Table of Contents
Introduction
Tolterodine is an antimuscarinic agent used primarily for the treatment of overactive bladder (OAB) with symptoms such as urinary urgency, urinary frequency, and urge urinary incontinence. It reduces involuntary bladder contractions by blocking muscarinic receptors in the urinary bladder, thereby increasing bladder storage capacity and improving urinary control.
Mechanism of Action (Step-wise)
- Tolterodine is administered orally and absorbed into the systemic circulation.
- The drug reaches the urinary bladder and binds to muscarinic cholinergic receptors.
- Muscarinic M2 and M3 receptors are present on detrusor smooth muscle cells.
- Under normal conditions, acetylcholine released from parasympathetic nerves binds to these receptors.
- Activation of M3 receptors increases intracellular calcium concentrations.
- Increased intracellular calcium causes contraction of the detrusor muscle during urination.
- Tolterodine competitively blocks muscarinic receptors, particularly M3-mediated responses.
- Acetylcholine-induced detrusor contractions decrease.
- Bladder smooth muscle relaxation increases during the filling phase.
- Functional bladder capacity increases.
- Episodes of urgency, frequency, and urge incontinence decrease.
- The overall effect is improved bladder storage and reduced symptoms of overactive bladder.
A key exam point is that tolterodine blocks muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Pharmacokinetics
Tolterodine is administered orally and is available in immediate-release and extended-release formulations. It undergoes hepatic metabolism primarily through CYP2D6 and CYP3A4. An active metabolite, 5-hydroxymethyl tolterodine, contributes significantly to therapeutic activity. Elimination occurs mainly through urine.
Clinical Uses
Tolterodine is used in:
- Overactive bladder
- Urinary urgency
- Urinary frequency
- Urge urinary incontinence
Adverse Effects
Common adverse effects include:
- Dry mouth
- Constipation
- Blurred vision
- Dry eyes
- Dizziness
Serious adverse effects may include:
- Urinary retention
- Tachycardia
- Cognitive impairment in susceptible individuals
- QT interval prolongation (rare)
Comparative Analysis
| Feature | Tolterodine | Oxybutynin | Mirabegron |
|---|---|---|---|
| Drug class | Antimuscarinic | Antimuscarinic | β3 agonist |
| Main target | Muscarinic receptors | Muscarinic receptors | β3 adrenergic receptors |
| Detrusor relaxation | Yes | Yes | Yes |
| Dry mouth | Moderate | Higher | Lower |
| Cognitive effects | Moderate | Higher | Minimal |
| Mechanism | Muscarinic blockade | Muscarinic blockade | β3 stimulation |
Tolterodine differs from mirabegron because it blocks muscarinic receptors rather than stimulating β3 receptors. Compared with oxybutynin, tolterodine generally causes fewer anticholinergic adverse effects while maintaining similar efficacy.
MCQs
1. Tolterodine belongs to which drug class?
a) β3 agonists
b) Antimuscarinics
c) α1 blockers
d) Diuretics
Answer: b) Antimuscarinics
2. Tolterodine primarily acts on:
a) Dopamine receptors
b) Muscarinic receptors
c) Histamine receptors
d) GABA receptors
Answer: b) Muscarinic receptors
3. Which bladder muscle is affected by tolterodine?
a) External urethral sphincter
b) Detrusor muscle
c) Pelvic floor muscle
d) Internal anal sphincter
Answer: b) Detrusor muscle
4. Acetylcholine normally causes:
a) Detrusor relaxation
b) Detrusor contraction
c) Renal vasodilation
d) Sodium retention
Answer: b) Detrusor contraction
5. Tolterodine is mainly used in:
a) Overactive bladder
b) Hypertension
c) Asthma
d) Parkinson disease
Answer: a) Overactive bladder
6. Tolterodine increases:
a) Urinary urgency
b) Functional bladder capacity
c) Histamine release
d) Renal filtration
Answer: b) Functional bladder capacity
7. A common adverse effect is:
a) Dry mouth
b) Hypercalcemia
c) Hypoglycemia
d) Bradycardia
Answer: a) Dry mouth
8. Tolterodine may cause:
a) Constipation
b) Hypernatremia
c) Polycythemia
d) Hyperthyroidism
Answer: a) Constipation
9. Tolterodine is metabolized primarily by:
a) CYP2D6 and CYP3A4
b) CYP1A2 only
c) Monoamine oxidase
d) Xanthine oxidase
Answer: a) CYP2D6 and CYP3A4
10. A serious adverse effect is:
a) Urinary retention
b) Hyperkalemia
c) Cataracts
d) Hypocalcemia
Answer: a) Urinary retention
11. Compared with mirabegron, tolterodine acts by:
a) β3 receptor stimulation
b) Muscarinic receptor blockade
c) Dopamine receptor blockade
d) Histamine receptor antagonism
Answer: b) Muscarinic receptor blockade
12. The primary therapeutic effect of tolterodine is:
a) Reduced bladder overactivity
b) Increased urine production
c) Enhanced renal blood flow
d) Increased sodium excretion
Answer: a) Reduced bladder overactivity
FAQs
What is the mechanism of action of tolterodine?
Tolterodine blocks muscarinic receptors in the bladder, reducing detrusor muscle contractions and improving bladder storage capacity.
Why is tolterodine used in overactive bladder?
It decreases urinary urgency, frequency, and urge incontinence by relaxing the detrusor muscle.
What receptors are primarily involved in tolterodine’s action?
Muscarinic receptors, particularly M3-mediated responses in the bladder.
What are common side effects of tolterodine?
Dry mouth, constipation, blurred vision, and dizziness.
How does tolterodine differ from mirabegron?
Tolterodine blocks muscarinic receptors, while mirabegron stimulates β3 adrenergic receptors.
Can tolterodine cause urinary retention?
Yes, excessive suppression of bladder contractions may lead to urinary retention.
References
Goodman & Gilman’s The Pharmacological Basis of Therapeutics
https://accessmedicine.mhmedical.com/book.aspx?bookid=3191
Katzung’s Basic and Clinical Pharmacology
https://accessmedicine.mhmedical.com/content.aspx?bookid=3382
Tripathi KD. Essentials of Medical Pharmacology
https://www.jaypeedigital.com
Harrison’s Principles of Internal Medicine
https://accessmedicine.mhmedical.com
